In summary, upregulating CAV-1 expression, reducing GSK-3β activity, and inhibiting excessive abnormal phosphorylation of Tau protein may be one of the molecular mechanisms of RSBFL for the prevention and treatment of AD. Here, MAPT is linked to Alzheimer disease.